Breast Cancer Canada Applauds Federal Commitment to Modernize Preventive Health Guidelines
Inclusion of experts, patient voices, and equity-focused policy reflects priorities long championed by Breast Cancer Canada
TORONTO, June 13, 2025--(BUSINESS WIRE)--Breast Cancer Canada proudly celebrates the federal government's response to the External Expert Review (EER) of the Canadian Task Force on Preventive Health Care, and the sweeping reforms it recommends to ensure preventive health guidance in Canada is more equitable, expert-informed, and responsive to real-world care.
"These systematic changes will save lives," said Kimberly Carson, CEO of Breast Cancer Canada. "We commend Canada's Federal Health Minister Marjorie Michel for making this a priority so early in her mandate, and we thank former Health Minister Mark Holland for working so closely with Breast Cancer Canada during his tenure. This milestone reflects years of dedicated advocacy. Bringing expert voices into task force decision-making is a long-overdue step toward ensuring that both science and lived experience shape public policy for Canadians."
The EER outlines recommendations, including stronger integration of subject matter experts, patient and public voices, and structured provincial input in guideline development. For Breast Cancer Canada and the REAL Canadian Breast Cancer Alliance—a national coalition of breast cancer experts—the report validates their persistent calls to reform how health guidance is developed and delivered in Canada. It also affirms that advocacy works: the federal government listened to patients and advocates calling for change.
This report embodies the transformative shift Breast Cancer Canada has relentlessly advocated for: expert-led, patient-centred, and equity-driven care informed by Canadian data and research. It signals a new era in Canadian breast cancer policy, one grounded in a national commitment to access for all.
"This report is a breakthrough," said Kimberly Carson, CEO of Breast Cancer Canada. "It recognizes that science and lived experience must work together to shape public health guidance. These recommendations reflect what Breast Cancer Canada, researchers, clinicians, and patients have been saying for years."
Founded by Breast Cancer Canada in 2023, REAL Canadian Breast Cancer Alliance brings together leading clinicians, patient advocates and data from across the country to advance evidence-based, equitable, and patient-informed breast cancer care. REAL Alliance was established to ensure that the latest research reaches patients faster and to help establish equitable, national standards of care for breast cancer.
Breast Cancer Canada is actively addressing the critical gap in Canadian-specific data by collecting and analyzing breast cancer outcomes across all stages and subtypes, with a focus on race, age, and geographic location.
"We are especially encouraged to see a formal shift toward expert engagement," said Shaniah Leduc, Chair of Breast Cancer Canada's Board of Directors. "Guidelines that impact patient outcomes must include disease-specific expertise. It's not just about input—it's about equity and access. Science moves quickly, and lives are affected when guidelines lag behind. A commitment to living guidelines ensures Canadians benefit from the most current knowledge in real-time."
"As someone whose survival depended on timely diagnosis and access to targeted treatment, I know firsthand the power of evidence-based care," said Kim MacDonald, breast cancer survivor and advocate with Breast Cancer Canada. "The recommendations released today are long overdue. Including expert insight and patient experience in national health guidance isn't just the right thing to do—it's what saves lives. My story could have ended differently without access to the testing and treatment I needed. Every Canadian deserves equity and access."
As the report notes, current guideline development in Canada is fragmented and often lacks the flexibility to reflect provincial realities or incorporate diverse forms of knowledge. The recommendations call for a pan-Canadian coordination hub and better integration with provincial screening programs, quality councils, and implementation bodies.
"When evidence, expert insight, and lived experience come together, patients benefit," Carson added. "We look forward to seeing these recommendations put into action and continuing our role in ensuring breast cancer care is equitable, evidence-based, and patient-informed."
Key Takeaways from the External Expert Review of Canada's Preventive Health Guidelines:
Formal inclusion of clinical subject matter experts in the Task Force's working groups to strengthen evidence interpretation and disease-specific expertise
Structured engagement of patients and community members, particularly from underrepresented groups, to bring real-world lived experience into national guideline development
Equity-focused topic selection and public accountability, ensuring preventive guidance addresses the realities of all people in Canada, especially those from equity-denied populations
Contextualizable and coordinated guidelines, enabling provinces and territories to implement evidence-based recommendations in a way that fits their own systems and structures
A phased transition to living guidelines, so recommendations keep pace with science and practice in real-time
Breast Cancer Canada remains a committed partner in this modernization effort, with ongoing investments in personalized screening research and the REAL Alliance—a multi-disciplinary expert body established to accelerate breast cancer progress through national collaboration. Breast Cancer Canada is a national charity dedicated to saving lives through science. Focused exclusively on breast cancer research, Breast Cancer Canada funds programs that advance earlier detection, better treatment, and improved outcomes for everyone affected by the disease. For more information, visit breastcancerprogress.ca.
About Breast Cancer Canada
Breast Cancer Canada is a national charity focused exclusively on breast cancer research, education, and awareness. Dedicated to advancing science that leads to earlier detection, more precise treatments, improved access to care, and better outcomes, the organization ensures that lived experience is reflected in research priorities. With no government funding, all progress is made possible through the generosity of donors. To learn more, visit breastcancerprogress.ca.
About REAL Canadian Breast Cancer Alliance
REAL (Research Excellence + Active Leadership) Canadian Breast Cancer Alliance is a national coalition of clinical and academic experts driving improvements in breast cancer care. Formed in 2023 by Breast Cancer Canada, REAL Alliance produces annual evidence-based clinical recommendations through a structured, consensus-driven process that reflects the latest in research and innovation. REAL Alliance is committed to advancing national standards of care and ensuring all Canadians benefit from the best available science. To learn more, visit realalliance.ca.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250613877344/en/
Contacts
Media Megan DunscombeBreast Cancer Canadamdunscombe@breastcancerprogress.ca
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
11 hours ago
- Hamilton Spectator
Health screening task force to relaunch next spring after report calls for reform
OTTAWA - The health minister is hoping to relaunch a federal task force responsible for providing health screening guidelines next spring, after an expert report said there is a pressing need for reform. The Task Force for Preventive Health Care provides clinical guidelines for primary care providers on screening and prevention measures for cancer and other diseases. The group came under fire in May 2024 for rejecting expert advice to lower the age for breast cancer screening. It maintained that routine breast cancer screening should start at age 50 and end after age 74, though it said younger women could seek a mammogram after weighing the risks and benefits of early screening. Experts and the Canadian Cancer Society had called for the minimum screening age to be lowered to 40. A number of provinces are already funding screening for women between the ages of 40 and 50. Mark Holland, the health minister at the time, called for the expert review last October and suspended the task force's work in early March while the review was underway. Health Minister Marjorie Michel said in a statement Friday that she's asked the public health agency to immediately begin work on implementing the report's recommendations, and to ensure the modernized task force is fully operational by next April. The expert report said the task force needs a clear mandate and should become an external advisory body with transparent governance and accountable processes. It calls for guidelines to be developed in co-ordination with provincial and territorial programs. It said health agencies, professional associations, specialist societies and the private sector all issue their own guidelines, creating uncertainty for health providers and patients alike. The report said the expert panel 'heard concerns that physicians with expertise in diagnosing and managing specific diseases were not consistently included in the task force's work' and called for greater engagement with subject matter experts. It also recommends changes to the membership of the task force itself. It said the Public Health Agency of Canada 'should launch open and transparent calls for nominations and conduct targeted outreach to engage professional, academic and community organizations identifying candidates from diverse backgrounds.' The report got positive reactions from advocacy groups, including the Canadian Cancer Society, which said it was pleased to see its recommendations included. 'This report reflects opportunities raised by many caring people and organizations who all share a common goal of making Canadians healthier and we're very hopeful for the future,' said the society's CEO Andrea Seale in a statement. Seale said the task force has a backlog of outdated guidelines that must be addressed and it's up to the government to ensure the reforms happen promptly. Dense Breasts Canada, an advocacy group that has been calling for revisions to the national breast cancer screening guidelines for years, said the expert panel's report is good news. 'The expert panel's recommendations set out a new direction for developing screening guidelines which reflect the latest evidence and are responsive to the needs of Canadians from all backgrounds,' said the group's executive director Jennie Dale, who made a presentation to the external review panel. The report said the task force should gradually adopt a 'living guidelines model' that responds continuously to new research findings. 'The COVID-19 pandemic demonstrated the importance of timely, evidence-based updates and highlighted the value of real-time synthesis and international collaboration in adapting to rapidly changing conditions and evidence,' the report said. Dr. Anna Wilkinson, an oncologist at the Ottawa Hospital, said in a media statement that by 'calling for formal expert involvement, the integration of diverse and evolving evidence, equitable care and ongoing evaluation,' the report paves the way for 'agile, 'living' guidelines that keep pace with scientific advancements.' This report by The Canadian Press was first published June 13, 2025. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Yahoo
13 hours ago
- Yahoo
Trade bill could trigger 'race to the bottom' in health standards, health groups warn
OTTAWA — Anti-smoking groups are warning the Carney government that its legislation to eliminate interprovincial trade barriers could undermine health standards unless it's amended to add new safeguards. The legislation, which the governing Liberals intend to push quickly through the House of Commons next week, looks to do two things — break down interprovincial barriers to trade and labour mobility and speed up approvals for major industrial projects, such as mines, ports and pipelines. The bill would allow provincial standards to displace federal ones to make it easier to sell Canadian-made goods within the country. But Rob Cunningham, senior policy analyst at the Canadian Cancer Society, said the current wording could lead to unintended consequences since provincial rules are sometimes weaker. He warns that, for example, it could prompt the return of products banned by federal regulation, such as those containing asbestos. "There's a federal measure banning asbestos in products, but provinces allow up to a certain per cent of asbestos in products," he said. "So that would mean that despite asbestos being banned in products for some years now, you could have asbestos return to products. That's not good." He also suggested the legislation could give tobacco companies space to bring back menthol or flavoured cigarettes, something that "shouldn't be happening." Cunningham said the bill should be changed to exempt federal health and environment standards and noted multilateral trade agreements typically contain such clauses. 'We are worried the tobacco (and) vape industry could take advantage of a less strict provincial standard to erode a stronger federal regulation that is protecting the health of Canadians across the country,' said Manuel Arango, vice-president of policy and advocacy at the Heart and Stroke Foundation. Ottawa could still create an exception for health through regulations after the bill is passed. It has not yet indicated it will do so. Cynthia Callard, head of Physicians for a Smoke-Free Canada, said she worries about the bill being rushed through Parliament since the devil "will likely be in the details in the regulations." "If these are not well constructed, there is a decided risk of health protection becoming collateral damage of a push for greater economic activity," she said. "Provincial and federal governments share jurisdiction for (health and environmental) issues, which is why it is important that there is a legal shield against a race to the bottom when it comes to protective regulations. I do not see this in the bill." The Bloc Québécois, NDP and Green Party are accusing Prime Minister Mark Carney's government of trying to ram the bill through Parliament too quickly without sufficient study. Carney promised to eliminate federal policies that act as a barrier to interprovincial trade by Canada Day. The Liberal government has not yet responded to requests for comment. On Friday, Intergovernmental Affairs Minister Dominic LeBlanc laid out the economic case for the trade aspects of the bill during debate in the House of Commons. He said the bill will remove "useless costs" and "regulatory confusion" that "hobble Canadians' ability to trade, connect and work wherever opportunity calls across our country." 'If a good is produced in compliance with provincial standards, it can move throughout the entire country without again having to go up against federal standards,' he said. He pointed to various levels of energy efficiency requirements that can stop products from being sold across provincial lines. He said an Ontario-made product that meets the province's "stringent energy efficiency requirements" could still be blocked from being sold in Quebec or Manitoba if it also does not meet federal standards. This report by The Canadian Press was first published June 13, 2025. Kyle Duggan, The Canadian Press Sign in to access your portfolio
Business Wire
13 hours ago
- Business Wire
Cerus Corporation Celebrates World Blood Donor Day 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2025. In 2005, the World Health Assembly designated June 14th as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. This year's theme, 'Give blood, give hope: together we save lives' is a reminder that hope is something we can all share. Cerus is proud to promote blood safety and expand donor eligibility, helping more people give, and more people receive the transfusions they need. The Company salutes the individuals, communities, and countries working together to make blood safety and availability a reality. 'A safe and reliable blood supply remains a cornerstone of every effective healthcare system around the globe, and one that would not be possible without the countless individuals that donate their time and blood. World Blood Donor Day is an opportunity to thank these individuals and to raise public awareness of the ongoing need for additional blood donations,' said Obi Greenman, Cerus' President and Chief Executive Officer. 'I am proud that Cerus is leading the development of pathogen reduction technologies for transfused blood components to help enable our blood center customers to deliver safe and effective blood components to patients.' According to the World Health Organization (WHO), more than 118.5 million blood donations are collected annually around the world, with 40% of these donations collected in high-income countries that account for only 16% of the global population. A wide variety of patients regularly receive blood transfusion, including cardiovascular surgery, transplant surgery, massive trauma, cancer, obstetric, and childhood anemia patients. 1 In recognition of World Blood Donor Day, Cerus hosted a blood drive earlier this week at its company headquarters and encourages everyone to participate in supporting blood product availability in their local communities. 1. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit and follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
